# Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)

> **NCT06595121** · PHASE1 · COMPLETED · sponsor: **Unither Pharmaceuticals, France** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** budesonide
- **DRUG:** budesonide
- **OTHER:** Activated Charcoal

## Key facts

- **NCT ID:** NCT06595121
- **Lead sponsor:** Unither Pharmaceuticals, France
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-13
- **Primary completion:** 2024-09-16
- **Final completion:** 2024-09-16
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06595121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06595121, "Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06595121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*